https://www.bioworld.com/rss en-us Biopharma and med-tech companies raising money in public or private financings, including: Erasca, Inhibrx, Rakovina, Rapidpulse, Revive, Tarsier, Variational AI, Vogenx, Xenter.  Vogenx, Xenter.]]> http://www.bioworld.com/articles/732729 Fri, 17 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732729-financings-for-july-17-2026 Biopharma and med-tech companies raising money in public or private financings, including: Advancell, Attovia, Braveheart, Cardiff, Crescent, Kestra, Neko Health, Q32, Senhwa, Think Surgical, Tytocare. http://www.bioworld.com/articles/732697 Thu, 16 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732697-financings-for-july-16-2026 Advancell Co. Ltd. has raised an oversubscribed $315 million series D round to accelerate its push to become a fully integrated global radiopharma developer, funding late-stage clinical development alongside isotope supply and manufacturing infrastructure. http://www.bioworld.com/articles/732694 Thu, 16 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732694-advancell-raises-315m-to-power-global-isotope-strategy Philina Lee, CEO, Advancell Advancell CEO Philina Lee (left). Credit: Advancell Co. Ltd. Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization. http://www.bioworld.com/articles/732692 Thu, 16 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732692-capital-remains-selective-in-barbell-biotech-market International currency symbols Biopharma and med-tech companies raising money in public or private financings, including: 410 Medical, Aeon, Autonomix, Chai, Draig, Erasca, Inhibikase, Lyora, Mighty, Poolbeg, Spero.  Chai, Draig, Erasca, Inhibikase, Lyora, Mighty, Poolbeg, Spero.]]> http://www.bioworld.com/articles/732615 Wed, 15 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732615-financings-for-july-15-2026 There is no doubt that investment into women’s health is increasing. According to a new report by W Group, in 2025, $1.55 billion in disclosed equity was raised by 85 women’s health companies, across more than 30 countries. However, challenges remain. http://www.bioworld.com/articles/732611 Wed, 15 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732611-womens-health-investment-climbs-but-funding-challenges-remain Businesswoman pressing dollar sign on touchscreen Lyora Therapeutics Inc. has launched with seed funding and a focus on genetic medicines targeting the root cause of inherited retinal diseases. The company has acquired advanced preclinical assets, which it plans to optimize and advance to be delivered locally and remain durable for life. http://www.bioworld.com/articles/732645 Wed, 15 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732645-lyora-therapeutics-launches-with-focus-on-retinal-diseases Hand holding lightbulb For decades, treatment options for osteoarthritis have followed a familiar path: As cartilage deteriorates and pain worsens, conservative therapies eventually give way to joint replacement surgery. Australian regenerative medicine company Integrant Pty Ltd. wants to change that trajectory. Rather than replacing damaged joints, the Sydney-based company is building a platform designed to regenerate cartilage and preserve joint function by combining biologics, medical devices and artificial intelligence. http://www.bioworld.com/articles/732670 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732670-integrant-targets-cartilage-repair-with-ai-biologics-platform Illustration of leg anatomy with target around knee Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China. http://www.bioworld.com/articles/732667 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732667-chinas-mindrank-raises-52m-series-b-to-advance-oral-glp-1 Blue digital dollar sign Biopharma and med-tech companies raising money in public or private financings, including: Agenus, Alto Neuroscience, Apnimed, Research Alliance, Virax. http://www.bioworld.com/articles/732603 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732603-financings-for-july-14-2026 Drug Farm Biotechnology Co. Ltd. closed a $55 million series D round to advance its AI-developed alpha-protein kinase 1 (ALPK1) inhibitor, DF-003, in a phase III trial for ROSAH syndrome, a rare genetic disease that can lead to blindness. http://www.bioworld.com/articles/732600 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732600-drug-farm-bags-55m-series-d-to-advance-ai-developed-alpk1-drug Blue dollar sign on white background Biopharma and med-tech companies raising money in public or private financings, including: Cue, Pharmnovo, Silo. http://www.bioworld.com/articles/732591 Mon, 13 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732591-financings-for-july-13-2026 Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China. http://www.bioworld.com/articles/732583 Mon, 13 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732583-chinas-mindrank-raises-52m-series-b-to-advance-oral-glp-1 Blue digital dollar sign The Global Health Innovative Technology (GHIT) Fund is investing approximately ¥2.86 billion ($18 million) in six R&D projects for the development of drugs for malaria, tuberculosis (TB) and neglected tropical diseases. http://www.bioworld.com/articles/732564 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732564-ghit-fund-buoys-malaria-tb-neglected-tropical-disease-research Various pills laid across a target Biopharma and med-tech companies raising money in public or private financings, including: Alchemab, Amprion. http://www.bioworld.com/articles/732538 Fri, 10 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732538-financings-for-july-10-2026 The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has announced the teams for the THRIVE (Treating Hereditary Rare diseases with In Vivo prEcision genetic medicines) program. With a commitment of up to $160 million over 5 years, THRIVE aims to accelerate solutions for rare genetic pediatric diseases across multiple technological approaches, clinical trial designs and deployment models. http://www.bioworld.com/articles/732544 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732544-arpa-h-program-supports-advances-for-rare-genetic-diseases Biopharma and med-tech companies raising money in public or private financings, including: Allotera, Bone Biologics, Leo Cancer, Lifeward, Oramed. http://www.bioworld.com/articles/732524 Thu, 09 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732524-financings-for-july-9-2026 For decades, treatment options for osteoarthritis have followed a familiar path: As cartilage deteriorates and pain worsens, conservative therapies eventually give way to joint replacement surgery. Australian regenerative medicine company Integrant Pty Ltd. wants to change that trajectory. Rather than replacing damaged joints, the Sydney-based company is building a platform designed to regenerate cartilage and preserve joint function by combining biologics, medical devices and artificial intelligence. http://www.bioworld.com/articles/732517 Thu, 09 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732517-integrant-targets-cartilage-repair-with-ai-biologics-platform Illustration of leg anatomy with target around knee Rybodyn Inc. has been awarded $1.3 million from the U.S. Department of War to advance preclinical development of two novel antibody-based therapies for lung cancer. http://www.bioworld.com/articles/732500 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732500-grant-supports-rybodyns-antibody-therapies-for-lung-cancer Lung cancer illustration Biopharma and med-tech companies raising money in public or private financings, including: Fore, Healome, Kalohexis, Semnur. http://www.bioworld.com/articles/732440 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732440-financings-for-july-8-2026 Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732472 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732472-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces Biopharma and med-tech companies raising money in public or private financings, including: Scribe. http://www.bioworld.com/articles/732426 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732426-financings-for-july-7-2026 The gene therapy specialist formerly known as EG427 has a new name and fresh momentum, after closing a €33 million (US$37.7 million) series C that will further advance clinical development of the lead program in chronic neuro-urology indications. http://www.bioworld.com/articles/732419 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732419-eg427-raises-377m-series-c-for-hsv-gene-therapy Bladder Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732473 Tue, 07 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732473-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Biobot Surgical. http://www.bioworld.com/articles/732446 Tue, 07 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732446-financings-for-july-7-2026 Biopharma and med-tech companies raising money in public or private financings, including: Abivax, Celea, Elicio, Tenon. http://www.bioworld.com/articles/732298 Mon, 06 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732298-financings-for-july-6-2026 Biopharma and med-tech companies raising money in public or private financings, including: AB Science, Abivax, Alvotech, Artan, Bridgebio, Cadrenal, Creative Medical, Materna, Neurogene, Oryzon, Owlet, Pictor, Telum. http://www.bioworld.com/articles/732280 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732280-financings-for-july-2-2026 Biopharma financings across all categories totaled $59.76 billion on 567 deals in the first half (H1) of 2026, more than double H1 2025’s $29.53 billion across 501 transactions. http://www.bioworld.com/articles/732277 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732277-h1-2026-biopharma-financings-double-from-last-year-approach-pandemic-highs Blocks with upward arrows Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company, months after winning approval for the country’s first invasive BCI system. http://www.bioworld.com/articles/732271 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732271-neuracle-eyes-shanghai-ipo-as-global-bci-funding-surges IPO puzzle pieces Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development. http://www.bioworld.com/articles/732358 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732358-artan-closes-seed-round-to-support-trna-platform Coins and seedling